甲状腺癌铁死亡的演变过程:新机制和机遇。
The evolving process of ferroptosis in thyroid cancer: Novel mechanisms and opportunities.
发表日期:2024 Aug
作者:
Lin Yin, Xiaodan Luo, Xian Zhang, Bomin Cheng
来源:
Cellular & Molecular Immunology
摘要:
甲状腺癌(TC)是一种常见的内分泌恶性肿瘤,全球发病率显着增加。铁死亡是一种新型的程序性细胞死亡,主要由铁过载和活性氧(ROS)依赖性脂质过氧化物积累引起。细胞铁死亡的主要表现是外膜破裂、线粒体皱缩、线粒体嵴缩小或消失,从而导致细胞死亡。铁死亡是肿瘤进展中的一种重要现象,与肿瘤相关信号通路的串扰深刻影响肿瘤进展、免疫效应和治疗结果。铁死亡在TC中的功能和机制也越来越受到人们的关注,主要体现在影响肿瘤的增殖、侵袭、迁移、免疫反应、治疗敏感性和遗传易感性方面。然而,目前对于铁死亡的形态学、生物学和机制途径的肿瘤生物学研究在TC中的深入程度远不如其他恶性肿瘤。因此,在这篇综述中,我们强调了铁死亡在 TC 进展中的新作用,包括诊断和治疗的新机制和潜在机会,并讨论了其局限性和前景。基于铁死亡的诊断和治疗策略有可能提供 TC 的补充管理。© 2024 作者。细胞与分子医学基金会和约翰·威利出版的《细胞与分子医学杂志》
Thyroid cancer (TC) is a prevalent endocrine malignancy, with a significant increase in incidence worldwide. Ferroptosis is a novel form of programmed cell death, primarily caused by iron overload and reactive oxygen species (ROS)-dependent accumulation of lipid peroxides. The main manifestations of cellular ferroptosis are rupture of the outer membrane, crumpling of the mitochondria and shrinkage or disappearance of the mitochondrial cristae, thus leading to cell death. Ferroptosis is an important phenomenon in tumour progression, with crosstalk with tumour-associated signalling pathways profoundly affecting tumour progression, immune effects and treatment outcomes. The functions and mechanisms of ferroptosis in TC have also attracted increasing attention, mainly in terms of influencing tumour proliferation, invasion, migration, immune response, therapeutic susceptibility and genetic susceptibility. However, at present, the tumour biology of the morphological, biological and mechanism pathways of ferroptosis is much less deep in TC than in other malignancies. Hence, in this review, we highlighted the emerging role of ferroptosis in TC progression, including the novel mechanisms and potential opportunities for diagnosis and treatment, as well as discussed the limitations and prospects. Ferroptosis-based diagnostic and therapeutic strategies can potentially provide complementary management of TCs.© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.